H.C. Wainwright Upgrades Iterum Therapeutics (ITRM) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
March 12, 2021 7:00 AM EST--NDA for Oral Sulopenem has PDUFA date of July 25, 2021-- Â Â --Cash Runway into First Half of 2023
--Company to host conference call today at 8:30amET--
DUBLIN, Ireland and CHICAGO, March 12, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31,... More
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
March 12, 2021 7:00 AM EST--NDA for Oral Sulopenem has PDUFA date of July 25, 2021--
  --Cash Runway into First Half of 2023
--Company to host conference call today at 8:30amET--
DUBLIN, Ireland and CHICAGO, March 12, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31,... More
